Edward Kelly

Courses Taught:

• PCEUT201
• PCEUT502
• PCEUT580
• PCEUT586
• PHG513

Education History:

BS, Biochemistry, UC-Riverside

MS, Biochemistry, UC-Riverside

PhD, Biochemistry, University of Washington

Biography: 

Dr. Kelly holds the rank of Professor at the University of Washington in the Department of Pharmaceutics (School of Pharmacy) and Adjunct Professor in the Department of Environmental and Occupational Health Sciences (School of Public Health). He is also an Investigator in the Kidney Research Institute at the UW School of Medicine and serves as Co-Director of the Pharmaceutical Bioengineering Extension Program.

The focus of the Kelly lab is ex vivo modeling of human organ function and drug/toxin-induced injury.  This research utilizes 3D-microfluidic “organs on chips” or microphysiological systems (MPS) as an alternative to animal testing. Our scope of work includes using MPS technologies to model how the kidney responds to microgravity on the International Space Station, how environmental toxins may modulate chronic kidney disease of unknown origin (CKDu) and the effects of glomerular disease on proximal tubule function. He is also part of a consortium to qualify a kidney MPS for defined contexts of use.

Selected Publications:

1. Arian CM, O’Mahony ET, Manwill PK, Graf TN, Oberlies NH, Cech NB, Clarke JD, Smith JG, Paine MF, Kelly EJ & Thummel KE. A gut response: Application of human enteroid monolayers to probe the mechanism of the goldenseal-mediated inhibition of metformin intestinal absorption. The Journal of Pharmacology and Experimental Therapeutics. https://doi.org/10.1016/j.jpet.2025.103597 2025. PMID: 40403579
2. Tsang YP, Aryeh KS, Wang K, Himmelfarb J, Yeung CK & Kelly EJ*. Enhancing therapeutic strategies and drug development for patients with kidney disease. Expert Opinion on Drug Safety https://doi.org/10.1080/14740338.2025.2525970  2025. PMID: 40568828
3. Hansen BC, Arian CM, Zeng Y, Takezawa MG, Theberge AB, Faustman EM, Thummel KE & Kelly EJ*. Leveraging RNA-seq deconvolution to improve complex in vitro model characterization. Journal of Biological Chemistry. https://doi.org/10.1016/j.jbc.2025.110510 2025. PMID: 40701251
4. O’Mahony ET, Arian CM, Aryeh KS, Wang K, Thummel KE & Kelly EJ*. Human intestinal enteroids: nonclinical applications for predicting oral drug disposition, toxicity and efficacy. Pharmacology and Therapeutics. https://doi.org/10.1016/j.pharmthera.2025.108879 2025. PMID: 40398537
5. Hansen BC, Aryeh KS, Lindell LX, Lau GK, Nicholson TM, Faustman EM & Kelly EJ*. In vitro models of the male reproductive system: applications for developmental and reproductive toxicology. Toxicological Sciences. https://doi.org/10.1093/toxsci/kfaf132 2025. PMID: 41002216
6. Mahadeo A, Tsang YP, Zheng AR, Arnzen S, Rodriguez AG, Warren MS, G?borik Z & Kelly EJ*. Human OAT1, OAT3, OAT4 and OATP1A2 Facilitate the Renal Accumulation of Ochratoxin A. Pharmaceutics. https://doi.org/10.3390/pharmaceutics17111474 2025. PMID: 41304811
7. Mahadeo A, Bammler TK, MacDonald J, Zheng AR, Yeung CK, Himmelfarb J & Kelly EJ*. Pervasive food contaminant ochratoxin-A induces energy crisis: Mitochondrial dysfunction in human primary proximal tubule cells. Toxicology Reports. https://doi.org/10.1016/j.toxrep.2025.102169  2025. PMID: 41341619
8. Jones-Isaac K, Yeung CK, Bain J, Lidberg K, Yang J, Wang L, MacDonald J, Bammler T, Thummel KE, Corn M, Ruiz MV, Countryman S, Koenig P, Mann HH, Himmelfarb J & Kelly EJ*. Effect of calcium oxalate microcrystals on kidney proximal tubule epithelial cell gene expression in microgravity. npj Microgravity. https://doi.org/10.1038/s41526-025-00543-3 2025. PMID: 41381544
9. Wang K, Tsang YP, Thummel KE, Kelly EJ, Mao Q & Unadkat JD. Effect of proinflammatory cytokines on intestinal drug transporters in human enteroid monolayers. Drug Metabolism and Disposition. https://doi.org/10.1016/j.dmd.2025.100208 2025. PMID: 41418738